Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade A 88.23 1.40% 1.22
CELG closed up 1.4 percent on Tuesday, January 15, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Jan 24

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CELG trend table...

Date Alert Name Type % Chg
Jan 3 200 DMA Resistance Bearish 9.70%
Jan 3 Gilligan's Island Sell Setup Bearish Swing Setup 9.70%
Jan 3 Crossed Above 20 DMA Bullish 9.70%
Jan 3 Crossed Above 50 DMA Bullish 9.70%
Jan 3 New Uptrend Bullish 9.70%
Jan 3 Expansion Breakout Bullish Swing Setup 9.70%
Jan 3 Pocket Pivot Bullish Swing Setup 9.70%
Jan 3 Volume Surge Other 9.70%
Jan 3 Above Upper BB Strength 9.70%
Jan 3 Gapped Up Strength 9.70%

Older signals for CELG ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 106.67
52 Week Low 58.59
Average Volume 10,056,603
200-Day Moving Average 81.8796
50-Day Moving Average 72.241
20-Day Moving Average 74.0495
10-Day Moving Average 84.417
Average True Range 3.0378
ADX 43.35
+DI 42.8295
-DI 11.7893
Chandelier Exit (Long, 3 ATRs ) 79.3366
Chandelier Exit (Short, 3 ATRs ) 67.7034
Upper Bollinger Band 96.9053
Lower Bollinger Band 51.1937
Percent B (%b) 0.81
BandWidth 61.731139
MACD Line 5.167
MACD Signal Line 3.1625
MACD Histogram 2.0045
Fundamentals Value
Market Cap 69.02 Billion
Num Shares 782 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 27.32
Price-to-Sales 6.42
Price-to-Book 9.26
PEG Ratio 0.67
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 90.47
Resistance 3 (R3) 90.29 89.37 90.09
Resistance 2 (R2) 89.37 88.80 89.46 89.97
Resistance 1 (R1) 88.80 88.45 89.09 88.98 89.84
Pivot Point 87.88 87.88 88.02 87.97 87.88
Support 1 (S1) 87.31 87.31 87.60 87.49 86.62
Support 2 (S2) 86.39 86.96 86.48 86.49
Support 3 (S3) 85.82 86.39 86.37
Support 4 (S4) 86.00